NLRP1抗体;NLRP1 Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12540(NLRP1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

NLRP1 antibodies target the NLRP1 (NOD-, LRR-, and pyrin domain-containing protein 1) inflammasome, a cytosolic multiprotein complex critical for innate immune responses. NLRP1 is one of the earliest identified pattern recognition receptors (PRRs) that senses pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). Upon activation, it assembles into an inflammasome, triggering caspase-1-mediated cleavage of pro-inflammatory cytokines (e.g., IL-1β, IL-18) and inducing pyroptosis. Dysregulation of NLRP1 has been linked to autoimmune and autoinflammatory disorders, including vitiligo, systemic sclerosis, and Alzheimer’s disease.

Autoantibodies against NLRP1 are detected in various autoimmune conditions, often correlating with disease severity. For example, in vitiligo, NLRP1 autoantibodies may contribute to melanocyte destruction by promoting inflammasome overactivation. Similarly, elevated NLRP1 antibody levels are observed in some neurological disorders, suggesting cross-talk between neuroinflammation and autoimmunity. The exact mechanisms driving NLRP1 autoantibody production remain unclear but may involve genetic susceptibility (e.g., NLRP1 polymorphisms), environmental triggers, or molecular mimicry.

Research on NLRP1 antibodies focuses on their diagnostic/prognostic potential and therapeutic targeting. Inhibitors blocking NLRP1 or downstream effectors (e.g., IL-1β) are under investigation for autoimmune and neurodegenerative diseases. However, challenges persist in understanding tissue-specific NLRP1 roles and antibody heterogeneity.